Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Ofatumumab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis: A Nationwide Cohort Study.

BACKGROUND AND OBJECTIVES B-cell-depleting therapy with anti-CD20 monoclonal antibodies is a highly effective and increasingly used treatment strategy for multiple sclerosis (MS); however, comparative effectiveness of anti-CD20 therapies is unclear. In this study, we aimed to evaluate the effectiveness of ofatumumab co...

Sahla El Mahdaoui, L. Pontieri, Jeppe Romme Christensen et al. · 0 citations
Review Open access Sep 2026

[Myelin oligodendrocyte glycoprotein antibody-associated disease].

Treatment differs from other inflammatory demyelinating CNS diseases such as multiple sclerosis (MS) or neuromyelitis optica spectrum disorder (NMOSD) despite overlapping symptoms despite overlapping symptoms.

M. Børresen, J. Christensen, K. Linnet et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.